Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-C137 in Advanced Solid Tumors
NCT06625593Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label trial of BG-C137 in solid tumor (3 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events, Maximum Tolerated Dose or Maximum Administered Dose of BG-C137 and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
BG-C137
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06625593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625593.